Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production

• Published in: Pharmaceutics Vol. 12; no. 6; p. 584
• Main Authors: Vicente-Pascual, Mónica, Gómez-Aguado, Itziar, Rodríguez-Castejón, Julen, Rodríguez-Gascón, Alicia, Muntoni, Elisabetta, Battaglia, Luigi, del Pozo-Rodríguez, Ana, Solinís Aspiazu, María Ángeles
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 23.06.2020; MDPI
• Subjects: Acids; Antibodies; Aqueous solutions; Bioavailability; Cornea; corneal inflammation; Gene therapy; Genetic engineering; Inflammation; interleukin-10; Lipids; Polyvinyl alcohol; polyvinyl alcohol (PVA); Proteins; Rheology; solid lipid nanoparticles; Topical medication; transfection; Tumor necrosis factor-TNF; Vectors (Biology); United Kingdom > UK; United States > US; Spain
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics12060584

One of the main challenges in gene therapy is the issue of delivery, and it is especially relevant for the success of gene therapy in the cornea. In the present work, eye drops containing biocompatible non-viral vectors based on solid lipid nanoparticles (SLNs) as gene delivery systems to induce the expression of interleukin 10 (IL-10) were designed to address the treatment of corneal inflammation. Two kinds of SLNs combined with different ligands (protamine, dextran, or hyaluronic acid (HA)) and formulated with polyvinyl alcohol (PVA) were prepared. SLN-based vectors were characterized in terms of size, adhesiveness, viscosity, and pH, before topical administration to wild type and IL-10 knock out (KO) mice. The formulations showed a homogenous particle size below 400 nm and a positive surface charge to favor bioadhesion; the incorporation of PVA improved the corneal penetration. After three days of treatment by topical instillation, SLN-based vectors mainly transfected corneal epithelial cells, HA-formulations being the most effective ones. IL-10 was capable of reaching even the endothelial layer. Corneal sections showed no histological change and formulations seemed to be well tolerated after repeated topical administration. These promising results highlight the possible contribution of non-viral gene augmentation therapy to the future clinical approach of corneal gene therapy.